Davis Polk advised the joint book-running managers in the offering, while Latham & Watkins LLP represented CytomX Therapeutics. CytomX Therapeutics, Inc. executed its $100 million public offering of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
